Studies of the Biology of Severe H1N1 Infection
One of the most vexing questions about H1N1 infection is why some patients fare poorly, while others recover uneventfully. It is likely that there are important genetic and biologic differences across patients that are incompletely understood when study is limited to clinical features. To help researchers form and test key hypotheses regarding the mechanisms underlying the clinical course of H1N1, we will promote the formation of a common biobank using standardized collection of blood samples for the assessment of genetic differences, gene expression, and circulating biomarkers of key biologic pathways, including inflammation, coagulation, ischemia-reperfusion, and endothelial activation. The biologic studies subgroup will further develop and disseminate standard, practical procedures to help investigators and clinicians institute REB-approved biologic sampling strategies.
As of January 31, 2010, worldwide more than 209 countries and overseas territories or communities have reported laboratory confirmed cases of pandemic influenza H1N1 2009, including over 15,174 deaths.